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Background / Objectives 
The Swiss Federal Office of Public Health has recommended vaccination against 
human papillomavirus (HPV) to prevent cervical cancer since 2007. To monitor the 
future public health impact of vaccination, baseline population-based data are 
required. The objectives of this study were to determine the prevalence of HPV and 
examine associated risk factors in women with cervical intraepithelial neoplasia stage 
3 or more severe lesions (CIN3+) in Switzerland. 
Methods 
We conducted a cross-sectional study with women diagnosed with CIN3+ in 
Switzerland. Ten pathology institutes from six cantons and three language regions 
participated. We conducted HPV typing on formaldehyde fixed-paraffin embedded 
specimens from 2014 and 2015. Women enrolled in 2015 were asked to complete a 
questionnaire. We described frequencies of HPV types. We also compared 
demographic characteristics and socioeconomic status (according to the Swiss 
neighbourhood index of socioeconomic position, Swiss-SEP) in the CIN3+plus group 
with the Swiss National Cohort (SNC) in 2014 and compared risk factors for HPV 
infection with the Swiss Health Survey (SHS) in 2012. 
Results 
We included 768 biopsies from 767 women aged 17-81 years with CIN3+ in 2014 
and 2015. Of these, 745 (97.0%) were positive for any HPV type, 5 (0.7%) were 
negative and 18 (2.3%) were not evaluable. Overall, 475/768 (61.8%) biopsies 
contained HPV 16 and/or 18 and 687 (89.5%) contained an oncogenic HPV type 
covered by the nonavalent HPV vaccine (16, 18, 31, 33, 45, 52, 58). In 2015, 273 
women completed a questionnaire. Compared with the SNC, fewer women with 
CIN3+ were born in Switzerland (49.0 vs. 63.4%; p<0.001) and more were single 
(48.9 vs. 28.1%; p<0.001), but mean Swiss-Sep index was similar (64.6±10.8 vs. 
 65.2±10.9; p=0.135). Amongst women with CIN3+, higher proportions reported ≥2 
sexual partners in the last 12 months (15.4% vs. 4.1%), smoking (38.5% vs. 22.0%) 
and hormonal contraception use in the last 12 months (35.5% vs. 22.4%) than 
women in the SHS. 
Conclusion 
This is the first study of HPV in women with CIN3+ covering all three language 
regions in Switzerland. Women with CIN3+ have levels of socioeconomic position 
that are similar to the Swiss general population but higher levels of some risk factors 
for HPV. Surveillance of HPV types in CIN3+ lesions is feasible and can be used to 
measure the future impact of HPV vaccination on clinical outcomes. 
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